Clinical Trial Update: Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 trial to assess safety and efficacy of HDP-101 in Chinese patients with relapsed or refractory multiple myeloma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Neoplasms

Drugs mentioned

• HDP-101

Snippet

Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Conditions: Multiple Myeloma and Other Plasma Cell Neoplasms | Phase 1 | Status: RECRUITING